As revealed by Qiu et al. [12], elevated ANRIL constitutes an indicator of the poor prognosis of ovarian cancer patients, whereas ANRIL inhibition could block the invasion and migration of ovarian cancer cells. The gene discussed is CDKN2B-AS1; the disease is ovarian carcinoma.